The Cuprizone Model: Reading Demyelination and Remyelination Without the Autoimmune Noise
Remyelination has become the most interesting frontier in multiple sclerosis. The approved therapies for relapsing disease are effective at...
preclinical research
What AAALAC Accreditation Actually Signals to Partners
AAALAC accreditation carries practical weight in preclinical drug development, and its implications for program quality extend beyond the credential...
BoNT in Postsurgical Pain: Mechanistic and Behavioral Findings from a Porcine SMIR Model
Botulinum toxin type A has been established as a therapeutic agent in spasticity, dystonia, and cosmetic indications for several decades. Its...
Adult Tissue and Sex Diversity in SCI: Translational Drug Development
Spinal cord injury presents one of the most challenging translational profiles in central nervous system drug development. The clinical need is...
Rethinking the Preclinical Package for Chronic Kidney Disease: Why Pigs belong in the conversation
Drug development for chronic kidney disease has entered a more ambitious phase. SGLT2 inhibitors, non steroidal mineralocorticoid receptor...
From Preclinical Signal to Clinical Confidence: What Pig Models Reveal That Rodents Can’t
The challenge in translational research is not generating data but generating actionable confidence.
Modeling diabetic neuropathy with mechanistic and translational considerations
Diabetic neuropathy affects nearly half of individuals living with diabetes, yet its underlying biological drivers remain only partially defined....
Why Pigs Are Becoming the Preferred Large Animal Model in Pain and Wound Healing Research
Pain and wound healing research demand models that accurately reflect human tissue structure, innervation, and functional recovery. While rodents...
When Rodents Aren’t Enough: How Translational Pig Models Reduce Late-Stage Risk
Drug development rarely fails because a compound lacked activity. More often, it fails because preclinical models failed to predict clinical reality.